The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Astellas Pharma
Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202.
 
Kei Muro
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International (Inst); PRA Health Sciences (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Trevor Feinstein
Leadership - OneOncology
Consulting or Advisory Role - Bayer; Bayer; Deciphera; Genzyme; Gilead Sciences; Lilly; Nektar
Speakers' Bureau - Sanofi; SOBI
Travel, Accommodations, Expenses - BeyondSpring Pharmaceuticals
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Merus NV; Moderna Therapeutics; Zymeworks
Research Funding - Astellas Pharma (Inst); Chungchun Intellicrown (Inst); Exelixis (Inst); IMPAC Medical Systems (Inst); Merck (Inst); Poseida (Inst); Sanofi (Inst); Synermore (Inst); Xencor (Inst)
 
Ioana Bonta
Stock and Other Ownership Interests - Esai Co; Iovance Biotherapeutics; Lilly; Verbe Therapeutics
Consulting or Advisory Role - Novartis; Roche
Patents, Royalties, Other Intellectual Property - R2 Technology
 
Satoru Kitazono
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Todd A. Gersten
No Relationships to Disclose
 
Leena Gandhi
Employment - NextPoint Therapeutics
Leadership - Bright Peak Therapeutics; Neximmune
Stock and Other Ownership Interests - Lilly
(OPTIONAL) Uncompensated Relationships - Accurius
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Jason Kaplan
No Relationships to Disclose
 
Seema Rao Gorla
Employment - Astellas Pharma
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Shubin Liu
No Relationships to Disclose
 
Michele Wozniak
No Relationships to Disclose
 
Anthony Lee
Employment - Pfizer; Roche/Genentech; Seagen
Stock and Other Ownership Interests - Pfizer; Roche/Genentech; Seagen
Patents, Royalties, Other Intellectual Property - U.S. Provisional Patent Application No. 17/159,128 Title: Methods for treatment of cancer with an ANTI-TIGIT antagonist antibody
 
Tejas Patil
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Pfizer; Regeneron; Takeda; Turning Point Therapeutics
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Gilead Sciences (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda